Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin

F. Nicoletti, M. O. Borghi, P. L. Meroni, W. Barcellini, C. Fain, R. Di Marco, R. Menta, H. U. Schorlemmer, G. Bruno, G. Magro, S. Grasso

Research output: Contribution to journalArticle

Abstract

Ten out of 20 (50%) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.

Original languageEnglish
Pages (from-to)232-236
Number of pages5
JournalClinical and Experimental Immunology
Volume91
Issue number2
Publication statusPublished - 1993

Fingerprint

Inbred NOD Mouse
Cyclophosphamide
Type 1 Diabetes Mellitus
Ly Antigens
Interleukin-2 Receptors
Immunosuppressive Agents
Interferon-gamma
Body Weight
Lymphocytes
gusperimus
Pharmaceutical Preparations

Keywords

  • autoimmune diabetes
  • cyclophosphamide
  • deoxyspergualin
  • FK-506
  • interferon-gamma
  • NOD/ WEHI mouse

ASJC Scopus subject areas

  • Immunology

Cite this

Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. / Nicoletti, F.; Borghi, M. O.; Meroni, P. L.; Barcellini, W.; Fain, C.; Di Marco, R.; Menta, R.; Schorlemmer, H. U.; Bruno, G.; Magro, G.; Grasso, S.

In: Clinical and Experimental Immunology, Vol. 91, No. 2, 1993, p. 232-236.

Research output: Contribution to journalArticle

Nicoletti, F, Borghi, MO, Meroni, PL, Barcellini, W, Fain, C, Di Marco, R, Menta, R, Schorlemmer, HU, Bruno, G, Magro, G & Grasso, S 1993, 'Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin', Clinical and Experimental Immunology, vol. 91, no. 2, pp. 232-236.
Nicoletti, F. ; Borghi, M. O. ; Meroni, P. L. ; Barcellini, W. ; Fain, C. ; Di Marco, R. ; Menta, R. ; Schorlemmer, H. U. ; Bruno, G. ; Magro, G. ; Grasso, S. / Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin. In: Clinical and Experimental Immunology. 1993 ; Vol. 91, No. 2. pp. 232-236.
@article{3d0fb02cd0714371bea4f513d4053191,
title = "Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin",
abstract = "Ten out of 20 (50{\%}) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.",
keywords = "autoimmune diabetes, cyclophosphamide, deoxyspergualin, FK-506, interferon-gamma, NOD/ WEHI mouse",
author = "F. Nicoletti and Borghi, {M. O.} and Meroni, {P. L.} and W. Barcellini and C. Fain and {Di Marco}, R. and R. Menta and Schorlemmer, {H. U.} and G. Bruno and G. Magro and S. Grasso",
year = "1993",
language = "English",
volume = "91",
pages = "232--236",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prevention of cyclophosphamide-induced diabetes in the NOD/WEHI mouse with deoxyspergualin

AU - Nicoletti, F.

AU - Borghi, M. O.

AU - Meroni, P. L.

AU - Barcellini, W.

AU - Fain, C.

AU - Di Marco, R.

AU - Menta, R.

AU - Schorlemmer, H. U.

AU - Bruno, G.

AU - Magro, G.

AU - Grasso, S.

PY - 1993

Y1 - 1993

N2 - Ten out of 20 (50%) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.

AB - Ten out of 20 (50%) 17-week-old female NOD/WEHI mice developed an acute form of autoimmune diabetes when injected with two large doses of cyclophosphamide (CY), given at 14-day intervals. If these mice were treated under a prophylactic regimen with 2.5 mg/kg body weight per day of the novel immunosuppressant deoxyspergualin (DSP) the onset of diabetes was completely prevented. Moreover, DSP-treated animals showed reduced signs of pancreatic insulitis, had lower percentages of splenic lymphoid cells (SLC) expressing IL-2 receptors and Ly-6C antigens on their surfaces, and these cells released lower amounts of interferon-gamma (IFN) when stimulated in vitro. These data, providing evidence for the capacity of DSP to protect NOD/WEHI mice from experimental autoimmune diabetes and to modulate histo-immunological pathogenic pathways, indicate DSP as a drug of potential interest in the treatment of human insulin-dependent diabetes mellitus.

KW - autoimmune diabetes

KW - cyclophosphamide

KW - deoxyspergualin

KW - FK-506

KW - interferon-gamma

KW - NOD/ WEHI mouse

UR - http://www.scopus.com/inward/record.url?scp=0027400806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027400806&partnerID=8YFLogxK

M3 - Article

C2 - 8428390

AN - SCOPUS:0027400806

VL - 91

SP - 232

EP - 236

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 2

ER -